Orgaran (Danaparoid Sodium)

Danaparoid Sodium, the active ingredient in Orgaran, is an anticoagulant presented as a intravenous solution for use in specialized clinical settings. It is employed in the management of certain clotting disorders and during procedures where blood clot prevention is critical. GNH USA supplies Orgaran as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide.

GNH USA supplies Orgaran as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide.

Orgaran is an anticoagulant that acts on the coagulation cascade to prevent pathological clot formation.

- Heparin‑induced thrombocytopenia (HIT): Provides anticoagulation when heparin therapy is contraindicated. - Cardiopulmonary bypass surgery: Reduces risk of intra‑operative clotting. - Vascular graft implantation: Helps maintain graft patency by limiting thrombus formation.

Adverse reactions to Orgaran are generally related to its anticoagulant activity and the intravenous route.

Common Side Effects: - Minor bleeding at infusion sites - Bruising - Nausea - Mild headache - Transient elevation of liver enzymes

Serious or Rare Side Effects: - Major hemorrhage - Thrombocytopenia - Allergic anaphylactic reaction - Disseminated intravascular coagulation (DIC) - Severe hypotension

When using Orgaran, clinicians should assess patient risk factors and monitor laboratory parameters closely.

- Renal impairment: Adjust monitoring frequency and consider dose modification. - Hepatic dysfunction: Observe liver function tests regularly. - Concomitant anticoagulants: Evaluate cumulative bleeding risk. - Recent surgery or trauma: Delay administration until hemostasis is secured. - Pregnancy: Use only if clearly indicated and benefits outweigh risks. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Orgaran may interact with other agents that affect hemostasis. Careful review of the patient's medication list is essential.

Major Interactions (Avoid): - Concurrent use with unfractionated heparin: Increases risk of severe bleeding. - Direct oral anticoagulants (DOACs) such as apixaban or rivaroxaban: Potentiates anticoagulant effect.

Moderate Interactions (Monitor Closely): - Antiplatelet drugs (aspirin, clopidogrel): May enhance bleeding tendency. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): Can aggravate gastrointestinal bleeding. - Thrombolytic agents: Heightened risk of hemorrhage. - Certain antibiotics (e.g., vancomycin): May alter plasma protein binding. - Herbal supplements containing ginkgo or garlic: Potentially increase bleeding risk.